by integrating HA, capsid protein (M1) and neuraminidase (NA
expressedininsectcells44â€“46.AlthoughpresentingproteinsinVL
structures enhanced their immunogenicity, it compromised th
purity of the vaccines considerably, as VLP structures als
integrated both baculovirus and Sf9 cell proteins. Elimination o
these unwanted proteins from the vaccine required extensiv
disassemblyandreassemblyprocessingofpurifiedVLPs,whichi
a constraint for the commercial scale manufacturing of vaccine
annually.Italso raises thecostand thetime ittakestobringth
vaccines to the market. The yield and the cost of variou
manufacturing processes and technologies are critical element
to ensure adequate supply of vaccine at an affordable cost
especially in a pandemic situation. This aspect of the vaccin
manufacturing has been discussed exhaustively in a repor
published by the Program for Appropriate Technology in Healt
(PATH)and is notcovered here47.